September 2026
M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30

Seyed Amir Raoufi: The Growing Role of CAC and Lp(a) in Preventive Cardiology

Seyed Amir Raoufi/LinkedIn

May 11, 2026, 13:29

Seyed Amir Raoufi: The Growing Role of CAC and Lp(a) in Preventive Cardiology

Seyed Amir Raoufi, Interventional Cardiologist, shared a post on LinkedIn:

“1. Patient Profile 

Age/Gender: middle age Male/Female.

Comorbidities: Controlled Hypertension (on medication), Non-Diabetic.

Clinical Status: Entirely asymptomatic.

Initial Lab Findings: Mildly elevated LDL-C; otherwise normal metabolic profile.

2. Diagnostic Work-up (Guideline 2026 Approach) 

To determine the necessity of Antiplatelet and Statin therapy, the following ‘Gatekeeper’ tests are prioritized:

Lipoprotein(a) [Lp(a)] Measurement: To assess genetic pro-thrombotic and pro-inflammatory risk.
Coronary Artery Calcium (CAC) Score: To quantify subclinical atherosclerotic burden (The ‘Power of Zero’ versus Plaque Presence).

3. Management Stratification

Scenario A: Low Genomic and Anatomic Risk

Criteria: Lp(a) less than 50 mg/dL AND CAC equals 0.
Antiplatelet: ASA Not Indicated.
Lipid Management: Statin therapy is optional or conservative. LDL-C Target: less than 100 mg/dL (2.6 mmol/L).

Scenario B: Moderate Anatomic Risk

Criteria: CAC score 1 – 99.
Antiplatelet: ASA usually withheld unless other high-risk features are present.
Lipid Management: Initiate Statin. LDL-C Target: less than 70 mg/dL (1.8 mmol/L).

Scenario C: High Genomic or Anatomic Risk

Criteria: Lp(a) more than 50 mg/dL OR CAC \ge 100.
Antiplatelet: Initiate Aspirin (81-100 mg) to mitigate the synergistic risk of thrombosis and plaque rupture (Class IIa).
Lipid Management: High-intensity Statin. LDL-C Target: less than 55 mg/dL (1.4 mmol/L).

4. Clinical Reasoning (Key Takeaways) 

The Synergistic Effect: Elevated Lp(a) acts as a pro-thrombotic modifier.

When Lp(a) is high, even non-obstructive plaques (confirmed by CAC more than 0) are more likely to cause an acute event due to impaired fibrinolysis.

Bleeding versus Ischemic Risk: In primary prevention, Aspirin is reserved for patients where CAC \ge 100 or elevated Lp(a) tips the balance in favor of ischemic protection over the risk of GI bleeding.

2026 Shift: We treat the Plaque Biology and Genetic Predisposition rather than just the LDL-C number.

Clinical Pearl: In 2026, the CAC score is no longer just “nice to have”; it is the decisive tool for preventing over-treatment with Aspirin in low-risk individuals and ensuring aggressive protection for those with subclinical disease.”

Seyed Amir Raoufi: The Growing Role of CAC and Lp(a) in Preventive Cardiology